AU6659198A - Compositions and methods for modulating cellular nf-$g(k)b activation - Google Patents

Compositions and methods for modulating cellular nf-$g(k)b activation

Info

Publication number
AU6659198A
AU6659198A AU66591/98A AU6659198A AU6659198A AU 6659198 A AU6659198 A AU 6659198A AU 66591/98 A AU66591/98 A AU 66591/98A AU 6659198 A AU6659198 A AU 6659198A AU 6659198 A AU6659198 A AU 6659198A
Authority
AU
Australia
Prior art keywords
compositions
activation
kappa
methods
modulating cellular
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU66591/98A
Other languages
English (en)
Inventor
Irit Alkalay
Yinon Ben-Neriah
Aaron Ciechanover
Anthony Manning
Frank Mercurio
Avraham Yaron
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Original Assignee
Yissum Research Development Co of Hebrew University of Jerusalem
Signal Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Research Development Co of Hebrew University of Jerusalem, Signal Pharmaceuticals LLC filed Critical Yissum Research Development Co of Hebrew University of Jerusalem
Publication of AU6659198A publication Critical patent/AU6659198A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Steroid Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Mobile Radio Communication Systems (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
AU66591/98A 1997-02-18 1998-02-18 Compositions and methods for modulating cellular nf-$g(k)b activation Abandoned AU6659198A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/802,322 US5932425A (en) 1997-02-18 1997-02-18 Compositions and methods for modulating cellular NF-κB activation
US08802322 1997-02-18
PCT/US1998/003163 WO1998036070A1 (en) 1997-02-18 1998-02-18 COMPOSITIONS AND METHODS FOR MODULATING CELLULAR NF-λB ACTIVATION

Publications (1)

Publication Number Publication Date
AU6659198A true AU6659198A (en) 1998-09-08

Family

ID=25183386

Family Applications (1)

Application Number Title Priority Date Filing Date
AU66591/98A Abandoned AU6659198A (en) 1997-02-18 1998-02-18 Compositions and methods for modulating cellular nf-$g(k)b activation

Country Status (8)

Country Link
US (1) US5932425A (https=)
EP (1) EP1009824B1 (https=)
JP (2) JP4560616B2 (https=)
AT (1) ATE391177T1 (https=)
AU (1) AU6659198A (https=)
CA (1) CA2281920C (https=)
DE (1) DE69839326T2 (https=)
WO (1) WO1998036070A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0920518A1 (en) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase ikk] signalsome
US6896899B2 (en) * 1996-12-31 2005-05-24 Antioxidant Pharmaceuticals Corp. Pharmaceutical preparations of glutathione and methods of administration thereof
EP0957901B1 (en) 1996-12-31 2009-11-18 Antioxidant Pharmaceuticals Corporation Pharmaceutical preparations of glutathione and methods of administration thereof
CA2330210A1 (en) * 1998-06-13 1999-12-23 Zarpex Biosciences Limited Proteasomal activity
CN102816743A (zh) * 1998-12-10 2012-12-12 信号药物公司 调节NF-κB的人遍在蛋白连接酶E3
US6630312B2 (en) 1999-08-10 2003-10-07 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US6468755B1 (en) 1999-08-10 2002-10-22 Joslin Diabetes Center, Inc. Method for identifying compounds for treatment of insulin resistance
US20030104622A1 (en) * 1999-09-01 2003-06-05 Robbins Paul D. Identification of peptides that facilitate uptake and cytoplasmic and/or nuclear transport of proteins, DNA and viruses
FR2801902B1 (fr) * 1999-12-01 2005-03-04 Centre Nat Rech Scient Procedes de criblages fonctionnels d'agents aptes a moduler l'activite des complexes ubiquitine-ligases scf et leurs applications
AU2001251612A1 (en) 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US20030044852A1 (en) * 2000-08-10 2003-03-06 Joslin Diabetes Center, Inc., A Massachusetts Corporation Methods for treatment of insulin resistance
US20060287337A1 (en) * 2001-11-09 2006-12-21 Proteologics, Inc. Trans-golgi network-associated processes, methods and compositions related thereto
AU2002349784A1 (en) * 2001-12-03 2003-06-17 Asahi Kasei Pharma Corporation Nf-kappab activating genes
FR2859733A1 (fr) * 2003-09-15 2005-03-18 Centre Nat Rech Scient Procede de criblage fonctionnel d'agents aptes a moduler l'activite des ubiquitine hydrolases et leurs applications
CN1926395B (zh) * 2004-03-02 2010-10-13 宝洁公司 用于固化高内相乳液的方法
FR2867783B1 (fr) * 2004-03-16 2008-02-01 Cytomics Systems Procede de criblage d'agent modulant l'ubiquitination de la proteine ikbalpha et moyens destines a la mise en oeuvre dudit procede
US20070060537A1 (en) * 2005-04-28 2007-03-15 Proteologics, Inc. Methods and compositions for inhibiting viral infections
US20100292306A1 (en) * 2005-05-24 2010-11-18 Carlson C George Compositions And Methods For The Treatment Of Muscular Dystrophy
US20070202593A1 (en) * 2006-02-27 2007-08-30 Research Development Foundation Cell-Targeted IKB and Methods for the Use Thereof
KR20100014565A (ko) * 2007-04-11 2010-02-10 알콘 리서치, 리미티드 알레르기성 비염 및 알레르기성 결막염을 치료하기 위한 ｔｎｆａ의 억제제 및 항히스타민의 용도
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
WO2010044892A1 (en) 2008-10-17 2010-04-22 President And Fellows Of Harvard College Diagnostic method based on large scale identification of post-translational modification of proteins
CN102548536A (zh) * 2009-10-01 2012-07-04 爱尔康研究有限公司 奥洛他定组合物及其用途
WO2020139830A2 (en) 2018-12-28 2020-07-02 Regeneron Pharmaceuticals, Inc. Treatment of respiratory disorders with arachidonate15-lipoxygenase (alox15) inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5122463A (en) * 1990-05-17 1992-06-16 Massachusetts Institute Of Technology Methods for trans-destabilization of specific proteins in vivo and dna molecules useful therefor
NZ257181A (en) * 1992-10-29 1997-07-27 Medical Res Council Transcription factor dp-1, dna, vectors and host cells therefor
DE4243770A1 (de) * 1992-12-23 1994-06-30 Behringwerke Ag Verfahren zur Herstellung von rekombinanten und synthetischen Peptiden und deren Verwendung
IL114615A0 (en) * 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
WO1997000690A1 (en) * 1995-06-23 1997-01-09 Tularik, Inc. Interleukin-1 receptor-associated protein kinase and assays
EP0920518A1 (en) * 1996-08-26 1999-06-09 Signal Pharmaceuticals, Inc. Stimulus-inducible i (kappa)b kinase ikk] signalsome

Also Published As

Publication number Publication date
DE69839326T2 (de) 2009-04-16
CA2281920A1 (en) 1998-08-20
WO1998036070A1 (en) 1998-08-20
US5932425A (en) 1999-08-03
HK1028784A1 (en) 2001-03-02
JP2010063461A (ja) 2010-03-25
EP1009824B1 (en) 2008-04-02
JP2001512319A (ja) 2001-08-21
CA2281920C (en) 2010-05-04
JP4560616B2 (ja) 2010-10-13
EP1009824A1 (en) 2000-06-21
DE69839326D1 (de) 2008-05-15
ATE391177T1 (de) 2008-04-15

Similar Documents

Publication Publication Date Title
AU6659198A (en) Compositions and methods for modulating cellular nf-$g(k)b activation
WO1996017072A3 (en) Recombinant alphavirus vectors
YU15299A (sh) Farmaceutski sastavi
WO1995007994A3 (en) Recombinant alphavirus vectors
AU688952B2 (en) Thrombin inhibitors
DK1032662T3 (da) Fremgangsmåder og sammensætninger til immunmodulation
AU7575698A (en) Peptides which enhance transport of an active agent across tissues and composi tions and methods of using the same
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
DE69414471D1 (de) Dichtungsanordnung zur Einführung von chirurgischen Instrumenten
AU4905097A (en) Thrombin inhibitors
EP0634835A3 (en) Low voltage high frequency amplifier and mixer with a single bias block and method.
CA2243469A1 (en) Encoding technique for software and hardware
AU7629694A (en) Compositions for treating corns, calluses and warts
DE69630955D1 (de) Immortalisierung bzw. desimmortalisierung von zellen
WO1997030082A3 (fr) Peptide antibacterien et antifongique
WO2000034447A8 (en) Human ubiquitin ligase e3 for the modulation of nf-kappa b
AU3036797A (en) Immortal avian cells
PL346246A1 (en) Modulating multiple lineage kinase proteins
AU4726797A (en) Prophylactic/remedial agent
DE69625230D1 (de) Thrombininhibitoren
EP2256202A3 (en) Stimulus-inducible i (kappa)b kinase ikk signalsome
AU3440593A (en) Methods and compositions for blocking amyloid protein ion channels
WO1994020115A3 (en) Hyaluronic acid used as a cancer treatment
AU2748297A (en) Legal claims processing system and methods of litigation management using the same
NO885640D0 (no) Framgangsmaate og sammensetninger for katodisk beskyttelse.